Equities analysts expect that Clementia Pharmaceuticals Inc (NASDAQ:CMTA) will announce earnings per share (EPS) of ($0.45) for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Clementia Pharmaceuticals’ earnings, with estimates ranging from ($0.50) to ($0.39). Clementia Pharmaceuticals posted earnings of ($0.37) per share in the same quarter last year, which would indicate a negative year-over-year growth rate of 21.6%. The firm is expected to report its next earnings report on Wednesday, March 20th.
According to Zacks, analysts expect that Clementia Pharmaceuticals will report full year earnings of ($1.63) per share for the current fiscal year, with EPS estimates ranging from ($1.78) to ($1.49). For the next year, analysts anticipate that the firm will post earnings of ($1.91) per share, with EPS estimates ranging from ($2.15) to ($1.64). Zacks’ EPS calculations are a mean average based on a survey of research analysts that follow Clementia Pharmaceuticals.
A number of equities research analysts recently weighed in on CMTA shares. Robert W. Baird started coverage on shares of Clementia Pharmaceuticals in a research note on Friday, January 18th. They issued an “outperform” rating and a $24.00 target price on the stock. Zacks Investment Research downgraded shares of Clementia Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, February 12th. Bloom Burton reaffirmed a “buy” rating on shares of Clementia Pharmaceuticals in a research note on Sunday, December 16th. Wedbush downgraded shares of Clementia Pharmaceuticals from an “outperform” rating to a “neutral” rating in a research note on Monday, February 25th. Finally, ValuEngine raised shares of Clementia Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Monday, February 25th. Four analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $25.00.
Shares of CMTA stock traded up $0.07 on Wednesday, hitting $25.87. The stock had a trading volume of 100 shares, compared to its average volume of 507,552. The company has a market cap of $982.55 million, a P/E ratio of -3.26 and a beta of 0.65. Clementia Pharmaceuticals has a 12-month low of $8.10 and a 12-month high of $26.57.
Large investors have recently modified their holdings of the business. NEA Management Company LLC increased its position in shares of Clementia Pharmaceuticals by 26.4% during the 4th quarter. NEA Management Company LLC now owns 2,707,734 shares of the company’s stock valued at $31,843,000 after purchasing an additional 566,037 shares during the last quarter. Baker BROS. Advisors LP boosted its stake in Clementia Pharmaceuticals by 62.1% in the 3rd quarter. Baker BROS. Advisors LP now owns 1,933,624 shares of the company’s stock worth $21,560,000 after purchasing an additional 741,029 shares during the period. Perceptive Advisors LLC bought a new position in shares of Clementia Pharmaceuticals during the 4th quarter valued at approximately $17,640,000. JPMorgan Chase & Co. boosted its position in shares of Clementia Pharmaceuticals by 17.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,037,047 shares of the company’s stock valued at $11,563,000 after acquiring an additional 155,336 shares during the last quarter. Finally, Artal Group S.A. boosted its position in shares of Clementia Pharmaceuticals by 22.8% during the 4th quarter. Artal Group S.A. now owns 850,000 shares of the company’s stock valued at $9,996,000 after acquiring an additional 158,000 shares during the last quarter. 94.46% of the stock is owned by institutional investors and hedge funds.
Clementia Pharmaceuticals Company Profile
Clementia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, develops treatments for patients suffering from bone disorders and other diseases. Its lead product candidate is palovarotene, an oral small molecule for the treatment of fibrodysplasia ossificans progressive, multiple osteochondromas, dry eye disease, and other diseases is in the Phase 3 MOVE Trial.
Featured Article: Yield Curve
Get a free copy of the Zacks research report on Clementia Pharmaceuticals (CMTA)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Clementia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clementia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.